Treatment of CB-1158, an ARG1 inhibitor under clinical trials, has been shown to restore the antitumor immunity exerted by T cells, both in vitro and in vivo syngeneic tumor model, and increase the population of pro-inflammatory macrophages [112]. The gene discussed is ARG1; the disease is neoplasm.